Allogeneic stem cell transplantation for the non-Hodgkin’s lymphomas and Hodgkin’s disease

Hale, G; Phillips, Gordon L.

doi:10.1053/ctrv.2000.0179

Cited by 9 publications

(3 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significant advances in the clinical management of indolent and aggressive NHL-utilizing cancer therapeutics have improved both response and survival rates for patients thus making it a chronic disease [2,3]. Autologous and allogeneic stem cell transplantation have shown to improve patient's outcomes including long-term survival [4][5][6][7][8]. Several treatment options promote disease remission or stability and can minimize side effects such as anemia, mucositis, and myelosuppression [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

et al. 2013

View full text Add to dashboard Cite

Background. The individual concerns of non-Hodgkin’s lymphoma (NHL) patients require identification and assessment during clinical research proposing to measure patients’ outcomes. The FACT-Lym was developed as part of the FACIT measurement system to address health-related quality-of-life (HRQL) issues for NHL patients.Patients and Methods. Items for the FACT lymphoma subscale (LymS) were generated from healthcare provider interviews, published literature, and content validity patient interviews. The FACT-Lym was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3).Results. Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item LymS to 15 items. The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment. Internal consistency coefficients for the 15-item LymS (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability. Correlations between LymS and SF-36 physical (r=.62) and mental (r=.48) summary scores reflect concurrent validity. Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores. The FACT-LymS differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse),P<0.001.Conclusions. These results support the validity of the FACT-Lym and suggest it will be a useful targeted endpoint in NHL clinical research.

show abstract

Section: Introductionmentioning

confidence: 99%

The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This finding confirmed previous reports on allogeneic grafting in patients with refractory lymphoma, and suggests a potent GvL effect, that comes at the price of a substantial rate of acute GvHD. 15 As our hopes of reduced GvHD with this approach were not substantiated, the protocol was modified by removing the interval between cytoreductive HDC and immunosuppressive conditioning for HSCT, as GvHD rates were not lower than expected in the initial protocol. The rationale of using BEAM followed immediately by 2 Gy total body irradiation (TBI) and fludarabine was to guarantee engraftment, as BEAM alone has been reported to be insufficiently immunosuppressive for stable engraftment in some patients.…”

Section: Introductionmentioning

confidence: 99%

High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation

Buser

Stangel

Bucher

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Patients with refractory/relapsing lymphoma are rarely cured by chemotherapy. High-dose chemotherapy (HDC) for tumor debulking followed by reduced-intensity conditioning (RIC) hematopoietic stem-cell transplantation (HSCT) has been advocated as a concept. We previously treated 10 patients (group A) with BEAM chemotherapy followed by delayed RIC HSCT at day 28. We now report on the subsequent 11 patients receiving BEAM followed immediately by fludarabine/total body irradiation and allogeneic HSCT (group B), and compare the outcome to group A patients. Non-hematological toxicity before engraftment was comparable, only gut toxicity was higher in group B. Days in aplasia, days on antibiotics and length of hospital stay were significantly longer in group A. Cumulative incidence of acute (GvHD) >or=grade II and incidence of chronic GvHD were lower in group B. At last follow-up, seven patients in group A were alive, with six of them in complete remission. In group B, nine patients were alive, seven of them in complete remission. No significant difference in estimated 3-year overall survival was seen. These data challenge the initial concept of debulking first and delaying allogeneic RIC HSCT. Allogeneic HSCT with standard BEAM conditioning is a valid alternative for patients with resistant/relapsed lymphoma, which might be considered earlier in the disease course.

show abstract

“…However, its sensitivity to change should be verified by evaluating its performance in other patient groups. (11,12). Los pacientes con linfoma, al igual que otros pacientes oncológicos tienen preocupaciones específicas que generan un deterioro físico, social, psicológico y funcional (13); sin embargo, hasta el momento no hay instrumentos válidos que permitan evaluar la calidad de vida en este tipo de pacientes en Colombia.…”

Section: Discussionunclassified

Validación de la escala FACT-Lym para la evaluación de la calidad de vida en pacientes colombianos con linfoma

Estupiñán

Enciso

et al. 2020

Rev. Fac. Med.

View full text Add to dashboard Cite

Introducción. Los instrumentos para medir la calidad de vida se deben validar antes de ser utilizados en diferentes contextos culturales. En la actualidad existe una escala específica (FACT-Lym) para medir la calidad de vida en pacientes con linfoma, sin embargo esta no ha sido validada en Colombia.Objetivo. Establecer las propiedades clinimétricas de la escala FACT-Lym en pacientes colombianos con linfoma. Materiales y métodos. Se realizó un estudio de validación de escalas según la teoría clásica de test. Se aplicó la escala FACT-Lym a 301 pacientes del Instituto Nacional de Cancerología diagnosticados con diferentes tipos de linfoma y se registraron sus datos sociodemográficos y clínicos. El análisis estadístico incluyó análisis factorial exploratorio, análisis factorial confirmatorio, validez de constructo, consistencia interna, confiabilidad test re-test y sensibilidad al cambio.Resultados. El análisis factorial exploratorio confirmó una estructura de dos factores de la escala, mientras que el análisis confirmatorio mostró un adecuado ajuste del modelo estructural. La consistencia interna se midió con el coeficiente alfa de Cronbach (>0.8 en la escala global y en cada uno de los factores). Se encontraron valores de correlación significativamente diferentes a cero entre la FACT-Lym y los dominios de la escala FACT-G. No se observaron cambios significativos en ninguno de los dominios de la FACT-Lym luego de completar o suspender el tratamiento.Conclusiones. La validación de la escala FACT-Lym en Colombia mostró que esta tiene una estructura factorial consistente y una adecuada confiabilidad. Sin embargo, su sensibilidad al cambio debe verificarse evaluando su desempeño en otras poblaciones.

show abstract

Allogeneic stem cell transplantation for the non-Hodgkin’s lymphomas and Hodgkin’s disease

Cited by 9 publications

References 119 publications

The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation

Validación de la escala FACT-Lym para la evaluación de la calidad de vida en pacientes colombianos con linfoma

Contact Info

Product

Resources

About